Abstract 834P
Background
Marginal zone lymphoma (MZL) is a relatively common group of inert B-cell non-Hodgkin’s lymphoma (B-NHL) originating from peripheral memory lymphocytes. Some patients cannot achieve complete remission or relapse quickly after standard first-line treatment. Studies have shown that the NF-KB signal pathway in MZL is in an abnormally activated state, while bortezomib is a proteasome inhibitor targeting the NF-KB pathway. This multicenter phase II clinical study evaluated the efficacy and safety of VR-CAP regimen in the first-line treatment of MZL, and explored the best beneficiaries of VR-CAP regimen (rituximab, cyclophosphamide, epirubicin, bortezomib and prednisone).
Methods
The patient received 6 cycles of VR-CAP first-line treatment. Each cycle lasts for 3 weeks, and rituximab (375 mg/m2) is given intravenously on the 0th day, cyclophosphamide (750 mg/m2) and epirubicin (70 mg/m2) are given intravenously on the 1st day, bortezomib (1.3 mg/m2) is given subcutaneously on the 1st and 4th days, and prednisone (100 mg) is given orally on the 1st to 5th days. The primary end point was 2-year progression-free survival (PFS), and the secondary end point was objective response rate (ORR), including complete response (CR) and partial response (PR); Total survival (OS) and security.
Results
At present, 23 patients were enrolled, the median age was 55 years (25-74 years). By February 2023, 15 patients had completed all six courses of treatment; 6 patients completed 4 courses of treatment; Two patients stopped treatment by themselves, and 22 patients could evaluate the curative effect. Sixteen patients (72.7%) and five patients (22.7%) achieved CR/CRu and PR respectively. PFS and OS were 82.2% and 82.0% respectively in two years. Among the 13 patients who have completed all the treatment, the common therapeutic adverse events are anemia (73.9%), gastrointestinal reaction (52.2%), thrombocytopenia (30.4%), pulmonary infection (21.7%), neurotoxicity (8.7%), rituximab-related rash (8.7%).
Conclusions
VR-CAP first-line treatment of lymphoma in the marginal region has a good effect, the objective response rate (ORR) is 95.5%, and the patient is well tolerated. All adverse events are mainly 1-2 grades.
Clinical trial identification
NCT04433156.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18